387 related articles for article (PubMed ID: 21074811)
1. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy.
You D; Jeong IG; Ahn JH; Lee DH; Lee JL; Hong JH; Ahn H; Kim CS
J Urol; 2011 Jan; 185(1):54-9. PubMed ID: 21074811
[TBL] [Abstract][Full Text] [Related]
2. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
McKiernan J; Wood CG
J Urol; 2013 Aug; 190(2):386-8. PubMed ID: 23702308
[No Abstract] [Full Text] [Related]
5. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Healy KA; Marshall FF; Ogan K
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
7. Editorial comment.
Akhtar NH; Tagawa ST
J Urol; 2011 Jan; 185(1):59. PubMed ID: 21074812
[No Abstract] [Full Text] [Related]
8. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
9. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy.
Chowdhury S; Harper PG; Choueiri TK
Nat Clin Pract Oncol; 2008 Dec; 5(12):698-9. PubMed ID: 18852722
[No Abstract] [Full Text] [Related]
10. Metastatic renal cell carcinoma: recent advances in the targeted therapy era.
Di Lorenzo G; Autorino R; Sternberg CN
Eur Urol; 2009 Dec; 56(6):959-71. PubMed ID: 19748725
[TBL] [Abstract][Full Text] [Related]
11. Presurgical therapy in metastatic renal cell carcinoma.
Jonasch E
Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
[TBL] [Abstract][Full Text] [Related]
12. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.
Levy DA; Swanson DA; Slaton JW; Ellerhorst J; Dinney CP
J Urol; 1998 Apr; 159(4):1168-73. PubMed ID: 9507824
[TBL] [Abstract][Full Text] [Related]
13. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
Bex A; Powles T
Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
[TBL] [Abstract][Full Text] [Related]
14. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
15. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
[TBL] [Abstract][Full Text] [Related]
16. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
[TBL] [Abstract][Full Text] [Related]
17. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.
Krambeck AE; Leibovich BC; Lohse CM; Kwon ED; Zincke H; Blute ML
J Urol; 2006 Nov; 176(5):1990-5; discussion 1995. PubMed ID: 17070231
[TBL] [Abstract][Full Text] [Related]
18. Editorial comment.
Singer EA; Srinivasan R; Bratslavsky G
J Urol; 2011 Jan; 185(1):66. PubMed ID: 21074200
[No Abstract] [Full Text] [Related]
19. [What is the impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?].
Oya M; Murai M
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1732-7. PubMed ID: 12402422
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
